Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 03, 2021 07:00 ET | Source: Passage Bio

Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights

- On track to initiate three Phase 1/2 clinical programs in the first half of 2021: PBGM01 for GM1 gangliosidosis (GM1), PBFT02 for frontotemporal dementia with granulin mutations, and PBKR03 for...
March 02, 2021 16:01 ET | Source: Passage Bio

Passage Bio to Participate in Upcoming March Investor Conferences

PHILADELPHIA, March 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
February 24, 2021 07:00 ET | Source: Passage Bio

Passage Bio to Report Fourth Quarter and Full-Year 2020 Financial Results on March 3, 2021

PHILADELPHIA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
February 19, 2021 07:00 ET | Source: Passage Bio

Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors

PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
February 08, 2021 07:00 ET | Source: Passage Bio

FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options

- Phase 1/2 trial expected to commence in first half of 2021 - Company has three INDs cleared for rare monogenic CNS disorders PHILADELPHIA, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc....
January 28, 2021 07:00 ET | Source: Passage Bio

Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations

– Second Product Candidate Expected to Enter Clinic in First Half of 2021 – Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal Dementia with Granulin (GRN) Mutations, a...
January 21, 2021 19:48 ET | Source: Passage Bio

Passage Bio Announces Pricing of Public Offering

PHILADELPHIA, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system...
January 19, 2021 16:06 ET | Source: Passage Bio

Passage Bio Announces Launch of Proposed Public Offering

PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system...
January 19, 2021 07:00 ET | Source: Passage Bio

Passage Bio to Host First of a Series of 2021 Virtual R&D Events on January 25

PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
January 11, 2021 07:00 ET | Source: Passage Bio

Passage Bio Announces Plan to Deliver on Multiple Meaningful Catalysts in 2021

– Investigational New Drug Applications (IND) submitted for PBFT02 for Frontotemporal Dementia with Granulin Mutation (FTD-GRN) and PBKR03 for Krabbe Disease – – Three clinical programs to begin in...